TY - JOUR
T1 - Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
AU - Ronner, Lukas
AU - Podoltsev, Nikolai
AU - Gotlib, Jason
AU - Heaney, Mark L.
AU - Kuykendall, Andrew T.
AU - O'Connell, Casey
AU - Shammo, Jamile
AU - Fleischman, Angela G.
AU - Scherber, Robyn M.
AU - Mesa, Ruben
AU - Yacoub, Abdulraheem
AU - Perkins, Cecelia
AU - Meckstroth, Shelby
AU - Behlman, Lindsey
AU - Chiaramonte, Matthew
AU - Salehi, Mahta
AU - Ziadkhanpour, Kimia
AU - Nguyen, Hellen
AU - Siwoski, Olivia
AU - Hung, Annie Kwok
AU - Martinez, Michelle Janania
AU - Nguyen, Jenny
AU - Patel, Sagar
AU - Kollipara, Revathi
AU - Dave, Ami
AU - Randall, Megan
AU - Grant, Michael
AU - Harrison, Mitchell
AU - Soto, Paola Fernandez
AU - Tremblay, Douglas
AU - Hoffman, Ronald
AU - Moshier, Erin
AU - Mascarenhas, John
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology
PY - 2020/5
Y1 - 2020/5
N2 - There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately use repeated-measures data or time-dependent modeling to answer these questions. To address this knowledge gap, we analyzed a retrospective database of 520 PV patients seen at 10 academic institutions across the United States. Taking hematologic laboratory data at ∼3-month intervals (or as available) for all patients for duration of follow-up, we used group-based trajectory modeling to identify latent clusters of patients who follow distinct trajectories with regard to their leukocyte, hematocrit, and platelet counts over time. We then tested the association between trajectory membership and hazard of 2 major outcomes: thrombosis and disease evolution to myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia. Controlling for relevant covariates, we found that persistently elevated leukocyte trajectories were not associated with the hazard of a thrombotic event (P 5.4163), but were significantly associated with increased hazard of disease evolution in an ascending stepwise manner (overall P 5.0002). In addition, we found that neither hematocrit nor platelet count was significantly associated with the hazard of thrombosis or disease evolution.
AB - There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately use repeated-measures data or time-dependent modeling to answer these questions. To address this knowledge gap, we analyzed a retrospective database of 520 PV patients seen at 10 academic institutions across the United States. Taking hematologic laboratory data at ∼3-month intervals (or as available) for all patients for duration of follow-up, we used group-based trajectory modeling to identify latent clusters of patients who follow distinct trajectories with regard to their leukocyte, hematocrit, and platelet counts over time. We then tested the association between trajectory membership and hazard of 2 major outcomes: thrombosis and disease evolution to myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia. Controlling for relevant covariates, we found that persistently elevated leukocyte trajectories were not associated with the hazard of a thrombotic event (P 5.4163), but were significantly associated with increased hazard of disease evolution in an ascending stepwise manner (overall P 5.0002). In addition, we found that neither hematocrit nor platelet count was significantly associated with the hazard of thrombosis or disease evolution.
UR - http://www.scopus.com/inward/record.url?scp=85089820800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089820800&partnerID=8YFLogxK
U2 - 10.1182/BLOOD.2019003347
DO - 10.1182/BLOOD.2019003347
M3 - Article
C2 - 32107559
AN - SCOPUS:85089820800
SN - 0006-4971
VL - 135
SP - 1696
EP - 1703
JO - Blood
JF - Blood
IS - 19
ER -